# Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

> **NCT03891979** · PHASE4 · WITHDRAWN · sponsor: **NYU Langone Health**

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Ciprofloxacin 500mg PO BID days 1-29
- **DRUG:** Metronidazole 500mg PO TID days 1-29

## Key facts

- **NCT ID:** NCT03891979
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06-25
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Suspended due to Primary Investigator's decision
- **Last updated:** 2020-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03891979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03891979, "Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03891979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*